Breaks Categories: News

MondayOct 05, 2026 12:03 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens BIO REBOOT Registration, Announces PDAOAI Presentations at Drug Discovery 2026 

Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development. Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will…

Continue Reading

MondayOct 05, 2026 9:50 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Provides Update on Phase II Ebola Trial of NV-387 Oral Gummies

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for treatment of the current Bundibugyo Ebolavirus "BDBV" outbreak and other Ebola viruses in the Democratic Republic of Congo. The company said the trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. Pasted markdown NanoViricides said NV-387 is designed to…

Continue Reading

ThursdayOct 01, 2026 11:56 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Selects DRCARE247 as Telemedicine Partner

HealthLynked (OTCQB: HLYK) , a healthcare technology company focused on AI-powered patient engagement, care coordination and provider connectivity, selected DRCARE247 as its telemedicine partner. The partnership will integrate virtual care into the HealthLynked mobile application and website, allowing users to move from AI-powered health guidance to provider discovery, appointment scheduling, virtual consultations and medical record management within a single platform. HealthLynked expects to begin launching the integrated telemedicine platform in selected geographic regions over the next three months, followed by expansion into additional U.S. markets, subject to provider availability and applicable state requirements. The integration is expected to work alongside…

Continue Reading

ThursdayOct 01, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. The offering generated approximately $4 million in gross proceeds before fees and expenses. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share, potentially providing an additional approximately $4 million in gross proceeds if fully exercised for cash. The company intends…

Continue Reading

WednesdaySep 30, 2026 10:39 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast 

Quantum BioPharma (NASDAQ: QNTM) Co-Founder and Executive Co-Chair Anthony Durkacz returned to The BioMedWire Podcast to discuss the company’s Lucid-MS drug candidate, which is advancing to a Phase 2 trial in multiple sclerosis patients, as well as the development and commercial opportunity surrounding unbuzzd(TM). Durkacz said Lucid-MS targets myelin and that the upcoming trial will mark the first time the drug is tested in patients with multiple sclerosis. He also highlighted clinical results for unbuzzd(TM), which is designed to accelerate alcohol metabolism, and said Quantum BioPharma owns approximately 20% of the company behind the product and has a 7% royalty…

Continue Reading

TuesdaySep 29, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating approximately $4 million in additional gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions,…

Continue Reading

ThursdaySep 24, 2026 11:52 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Oncology Pipeline Following Nasdaq Listing as Xlife Sciences (SIX: XLS) Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps and remains an important part of its portfolio strategy. Xlife Sciences also reported operational and scientific progress across its portfolio during the first half of 2026, including developments at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio comprises 416 patents and patent…

Continue Reading

ThursdaySep 24, 2026 9:40 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., appointed Michael Zapolin as CEO. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. Former CEO Richard Buzbuzian is assisting with the transition to a publicly listed company, which is scheduled to go effective in the next quarter. Unbuzzd markets unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. The company said…

Continue Reading

WednesdaySep 23, 2026 11:53 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF) Awarded Digital Health Innovation Fund Grant for AI-Driven Oncology Platform 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF), together with Canada's Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, were awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute to support development of Onco SynoGraph AI-driven oncology platform. The reimbursement-based grant covers up to 25% of an estimated $3.5 million project budget. The project will advance SynoGraph using federated learning and causal AI to…

Continue Reading

WednesdaySep 23, 2026 9:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, which will cover OMAI market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships and contribution to shareholder value. OMAI core capabilities and initial platform were developed within Lantern clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is expanding into additional diseases, therapy…

Continue Reading